{"company": {"org_id": "T000248868", "org_name_cn": "上海君实生物医药科技股份有限公司", "org_short_name_cn": "君实生物", "org_name_en": "Shanghai Junshi Biosciences Co.,Ltd.", "org_short_name_en": "Junshi Biosciences", "main_operation_business": "新药的研发及相关技术的转让和服务，新药的生产和销售。", "operating_scope": "　　生物医药的研发，并提供相关的技术开发、技术咨询、技术转让、技术服务，从事货物及技术的进出口业务。药品批发，药品委托生产。（详见药品上市许可持有人药品注册批件）【依法须经批准的项目，经相关部门批准后方可开展经营活动】", "district_encode": "310115", "org_cn_introduction": "上海君实生物医药科技股份有限公司的主营业务是新药的研发及相关技术的转让和服务，新药的生产和销售。公司的主要产品是特瑞普利单抗、氢溴酸氘瑞米德韦片、Tifcemalimab、阿达木单抗、昂戈瑞西单抗、重组人源化抗IL-17A单克隆抗体、重组人源化抗PD-1、VEGF双特异性抗体、靶向ANGPTL3mRNA的siRNA药物、重组人源化抗CGRP单克隆抗体、PI3K-α抑制剂、重组人源化抗Claudin18.2单抗-MMAE偶联剂。公司拥有175项已授权专利，其中129项为境内专利，46项为境外专利。公司专利覆盖新药蛋白结构、制备工艺、用途、制剂配方等，为公司产品提供充分的和长生命周期的专利保护。", "legal_representative": "熊俊", "general_manager": "邹建军", "secretary": "王征宇", "established_date": 1356537600000, "reg_asset": 1026689871.0, "staff_num": 2578, "telephone": "86-21-61058800-1153", "postcode": "200126", "fax": "86-21-61757377", "email": "info@junshipharma.com", "org_website": "www.junshipharma.com", "reg_address_cn": "上海市浦东新区中国(上海)自由贸易试验区蔡伦路987号4层", "reg_address_en": null, "office_address_cn": "上海市浦东新区平家桥路100弄6号7幢16层", "office_address_en": null, "currency_encode": "019001", "currency": "CNY", "listed_date": 1594742400000, "provincial_name": "上海市", "actual_controller": "熊俊 (9.97%)，熊凤祥 (4.17%)", "classi_name": "民营企业", "pre_name_cn": null, "chairman": "熊俊", "executives_nums": 19, "actual_issue_vol": 87130000.0, "issue_price": 55.5, "actual_rc_net_amt": 4496978300.0, "pe_after_issuing": null, "online_success_rate_of_issue": 0.04441817, "affiliate_industry": {"ind_code": "BK0042", "ind_name": "生物制品"}}}